What Vexev does
Vexev builds VxWave, a robotic tomographic ultrasound platform that uses AI signal processing to let non-specialist clinical staff perform vascular imaging, starting with dialysis vascular-access mapping. The system produces a 3D vascular model and report at the point of care. In its CANSCAN feasibility trial of 120 chronic kidney disease patients, the company reports a 94% scanning success rate and 100% data adequacy. Vexev is a UNSW spinout founded in Sydney in 2018 and has partnered with U.S. Renal Care, the third-largest U.S. dialysis provider.
Vexev is a healthcare tool on Falcoscan. AI-guided robotic ultrasound that lets non-specialists scan for vascular disease. Falcoscan rates Vexev with an Opportunity score of 84/100, a Saturation score of 11/100, and a Wrapper-risk score of 9/100. Market signal: hot. Vexev is founded in 2018, currently at Series_a stage. Pricing: Paid.